- Home
- CMMB vs BNGO Comparison
CMMB vs BNGO Comparison
Compare CMMB & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- BNGO
- Stock Information
- Founded
- CMMB 2004
- BNGO 2003
- Country
- CMMB Israel
- BNGO United States
- Employees
- CMMB N/A
- BNGO N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- BNGO Biotechnology: Laboratory Analytical Instruments
- Sector
- CMMB Health Care
- BNGO Industrials
- Exchange
- CMMB Nasdaq
- BNGO Nasdaq
- Market Cap
- CMMB 22.0M
- BNGO 24.3M
- IPO Year
- CMMB N/A
- BNGO 2018
- Fundamental
- Price
- CMMB $3.02
- BNGO $3.88
- Analyst Decision
- CMMB Strong Buy
- BNGO Buy
- Analyst Count
- CMMB 2
- BNGO 5
- Target Price
- CMMB $26.50
- BNGO $7.67
- AVG Volume (30 Days)
- CMMB 108.4K
- BNGO 159.3K
- Earning Date
- CMMB 08-14-2025
- BNGO 08-14-2025
- Dividend Yield
- CMMB N/A
- BNGO N/A
- EPS Growth
- CMMB N/A
- BNGO N/A
- EPS
- CMMB N/A
- BNGO N/A
- Revenue
- CMMB N/A
- BNGO $27,426,000.00
- Revenue This Year
- CMMB N/A
- BNGO N/A
- Revenue Next Year
- CMMB N/A
- BNGO $20.81
- P/E Ratio
- CMMB N/A
- BNGO N/A
- Revenue Growth
- CMMB N/A
- BNGO N/A
- 52 Week Low
- CMMB $3.02
- BNGO $2.68
- 52 Week High
- CMMB $10.20
- BNGO $30.52
- Technical
- Relative Strength Index (RSI)
- CMMB 19.63
- BNGO 58.90
- Support Level
- CMMB $3.32
- BNGO $3.69
- Resistance Level
- CMMB $3.86
- BNGO $4.38
- Average True Range (ATR)
- CMMB 0.28
- BNGO 0.30
- MACD
- CMMB -0.03
- BNGO 0.05
- Stochastic Oscillator
- CMMB 2.65
- BNGO 64.29
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About BNGO Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.